VectorY’s Post

🚨 Only 10 spots left! Time is running out to register for the Fluid & Imaging Biomarkers in Neuroscience Summit happening in just 2 weeks! 🚀 Join a close-knit community of translational & clinical researchers, biomarker experts, and industry leaders to discuss the latest challenges and breakthroughs in neurodegenerative and neuroinflammatory drug development. 💡 Key takeaways include: 🧠 Discover how leading neuroscience biopharma are harnessing the power of advancing biomarker research to innovate CSF, plasma, and imaging markers of neurodegeneration and neuroinflammation 🔬 Uncover opportunities for novel technologies to be employed, such as diffusion-weighted imaging and population proteomics 🤝 Network with experts, present a poster, and shape the future of CNS biomarker discovery With workshop spots filling fast, secure your place this week; register here: https://ter.li/a490zm Join Leaders: Pfizer, APRINOIA Therapeutics, Takeda, AC Immune, Tranquis Therapeutics, Inc., The Michael J. Fox Foundation for Parkinson's Research, Biogen, Regeneron, PTC Therapeutics, Inc., Eli Lilly and Company, Eisai US, Novartis, Alector, Foundation for the National Institutes of Health & so many more! #CNS #Biomarkers #Neuroinflammatory #Neurodegenerative

The EQT Dementia Fund visited the AD/PD - Advances in Science & Therapy conference last week. It's great to observe that the amount of visitors continues to grow, and that the entire drug development ecosystem was present, including the leading KOLs, governmental organizations, pharmaceutical companies, start-ups, foundations, venture philanthropists, and investors. We saw interesting progress across the board - are we entering the age of neuroscience? In the coming weeks, I will share some of our thoughts on AD/PD, which includes topics like: - Prasinezumab data (Roche's anti-alpha-syn antibody) - Additional donanemab (Lilly's anti-amyloid antibody data analyses - Gamma secretase modulation (& Roche's small molecule phase 1 data) - Henne Holstege’s 100-plus research - Jeffrey Cummings’ update on the Alzheimer's disease drug development pipeline - Preliminary phase 1/2 data on Prevail's progranulin gene therapy & Vesper's sortiline small molecule - Phase 2 readout of Vivoryon's AD small molecule drug - Phase 2 readout of Amylyx's ALS small molecule drug - Trontinemab update (Roche's anti-amyloid antibody with TfR shuttle) Please feel free to reach out in case I'm missing an obvious topic! EQT Group EQT Life Sciences #science #technology #dementia #neuroscience #treatments #innovation

🚀 Partnerships of the week: 1️⃣ Iambic Therapeutics x Lundbeck In a powerful collaboration, Iambic Therapeutics and Lundbeck have teamed up to leverage AI for drug discovery, specifically targeting brain diseases. This partnership aims to combine cutting-edge artificial intelligence with deep scientific expertise to accelerate the development of novel therapeutics for neurological disorders. 👉 Learn more: Link in comments 2️⃣ Evotec x Novo Nordisk Evotec and Novo Nordisk are entering a technology development partnership focused on stem cell-based therapies. Together, they aim to create off-the-shelf cell therapy products for clinical and commercial use, with the goal of advancing breakthrough therapies in regenerative medicine. 👉 Learn more: Link in comments #biotech #pharma #drugdiscovery #AI #stemcelltherapy #innovation #collaboration

And that’s a wrap from us! 🤝What an incredible period of collaboration!Two conferences ( #biotrinity by OBN (UK) Ltd and Immuno by Oxford Global ) filled with insightful discussions with CROs, Biotechs and Pharma on how we, Cell Signaling Technology (CST), generate momentum for drug development workflows with strong validated solutions and unique innovations within #oncology , #neurology, #Celltherapy and #immunology. 🧩From disease modalities to biomarker discovery, and high throughput imaging, it's clear de-risking your drug discovery workflow is critical for every scientific discovery and development! ⭐️Excited to continue pushing boundaries and accelerate new therapy development for the most difficult diseases of the current day. 🎯Did you miss us? Reach out directly! #DrugDevelopment #Biotech #Pharma #CRO #Innovation #immunoassays

https://lnkd.in/eJSp_sFX Join our fantastic team of scientists as we pioneer PROTAC degrader molecules in devastating neurological diseases! ARV-102 is the first oral/ BBB penetrant PROTAC in clinical development for PSP/ PD. Come work with us to pioneer degraders in Huntington's, Alzheimer's, Parkinson's, ALS, and more. The time is now for small molecule degradation of mHTT, tau, alpha-synuclein, neuroinflammatory proteins! We can uniformly distribute across the brain where genomic modalities struggle to go after oral dosing. #PROTAC;#Arvinas

🌌 BPGbio, Inc.'s NAi platform: The NAi Process 🌌 BPGbio, Inc.'s NAi platform is digitalizing patient biology – using clinically annotated unbiased patient samples and causal AI to identify biological signals within the noise of billions of patient data points; revealing hidden cause and effect relationships that fuel drug discovery and de-risk drug development. The NAi process: Capture, generate, identify, and validate. All done using bias-free patient samples. For more information about BPGbio, Inc.'s NAi platform visit: https://lnkd.in/gvTXPEEf 👉 PARTNER WITH US ON YOUR DRUG DEVELOPMENT JOURNEY! #NAiInterrogativeBiology #AI #Biotechnology #Multiomics #SpatialOmics #Oncology #Neurology #RareDisease #Cancer #Biomarker #Biopharma #Techbio #Biotech #TPD #MitochondrialMedicine #ProteinHomeostasis #Proteostasis #DrugDiscovery #Therapeutics

🔬 **miRNA-Based Therapeutics: A Game Changer in Precision Medicine** 🔬 The field of microRNA (miRNA)-based therapeutics is revolutionizing our approach to treating diseases at the molecular level. By targeting miRNA pathways, we can modulate gene expression with precision, offering promising solutions for complex diseases like cancer, cardiovascular conditions, and neurological disorders. Key strategies include: - **Biogenesis Inhibition**: Using small-molecule inhibitors to halt miRNA production at its source. - **Functional Inhibition**: Leveraging anti-miRs, sponges, and masks to block miRNA activity. - **miRNA Replacement**: Restoring lost miRNA function with synthetic mimics. These advances open new doors for personalized treatment options, providing tailored therapeutic strategies based on a patient's unique genetic profile. 🚀 Exciting times ahead for the future of RNA-based therapies! #RNA #miRNA #Biotech #PrecisionMedicine #Therapeutics #Innovation #HealthcareTech #MolecularBiology.

This week I had the privilege of visiting Neus Martínez Bosch at PRBB (Barcelona Biomedical Research Park) to conduct a demonstration of our SimplePlex ELISA instrument, #Ella. It was exciting to witness the shift from manual analysis using Elisa kits to this next-generation benchtop automated platform. 🤝 Ella offers significant advantages: 💻 The platform eliminates manual steps, which increases accuracy and reproducibility; 🧪 Ella's Simple Plex™ assays are fully validated and offer sensitivity and multi-analyte analysis capability; ⏰ Ella can assay up to 8 analytes simultaneously in less than 90 minutes; 🚀 Minimal training required. Start increasing your lab productivity from day one! 📈 Excellent results for the following research areas: Cell Therapy Research, Neuroscience Research, Preclinical Research, Inflammatory Biomarker Research, Cancer Research, and Bioprocess Testing. #ELISA #SimplePlex #AutomatedAssays #LabAutomation #PrecisionResearch #CuttingEdgeTechnology #ScientificInnovation #ResearchAndDevelopment #CellTherapyResearch #NeuroscienceResearch #PreclinicalResearch #InflammatoryBiomarkerResearch #CancerResearch #BioprocessTesting #LifeSciences #DrugDiscovery #ClinicalTrials #Pharmaceuticals #ScientificResearch #MedicalInnovation #LabTesting #BiomedicalResearch

👏 Cellino is thrilled to share news that the preprint publication of “Considerations for the development of iPSC-derived cell therapies: A review of key challenges by the JSRM-ISCT iPSC Committee'' is now available on ScienceDirect. Co-authored by Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, and Bar Makovoz, PhD, our Principal Product Manager, and the JSRM-ISCT iPSC Committee, this collaborative review investigates the evolving needs in developing autologous iPSC-based therapies. The white paper explores global regulatory frameworks, quality control tests, and manufacturing considerations necessary for producing safe and economically viable iPSC-based therapies. 📄 Read the preprint publication here: https://bit.ly/4bccxYK We are excited for the potential impact of this work and are grateful to The Japanese Society for Regenerative Medicine (JSRM) - ISCT, International Society for Cell & Gene Therapy iPSC Committee for supporting research that accelerates patient access to personalized regenerative medicines. #JSRM #ISCT #RegenMed #Biotech #Autologous #Biomanufacturing #MachineLearning #PersonalizedMedicine #YourCellsYourCure #CellinoBio